Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07585552

Anesthesia Type and HoLEP Outcomes: A Multi-Center Study

1. What is this study about, and why is it required?

The goal of this observational study is to learn if anesthesia type (e.g., general anesthesia, spinal anesthesia) affects the safety and efficiency of HoLEP surgery. The main question it aims to answer is:

- Is a particular type of anesthesia related to less or more bleeding during the surgery? 2. What will be assessed to answer the main question of this study? (Outcome measure(s))

2.1. Primary outcome measure of this study is:

- Change in the hemoglobin level perioperatively.

2.2. Secondary outcome measures are: * Requirement for the usage of any vasoactive medication due to low blood pressure * Time passed until discharge. * Time passed until the removal of the bladder drainage catheter. * Ratio of the unwanted events that require additional intervention other than medication, fluids, or blood transfusions (Complications, Clavien-Dindo Grade III or higher). * International symptom questionnaire score 3 months after surgery. * Quality of life (QoL) score 3 months after surgery. * Peak urinary current velocity (Qmax) and post-void residual volume measurement 3 months after surgery. 3. Can anyone participate in this study?

Voluntary participants should meet the following criteria:

* Being older than 18 years old. * Having bothersome lower urinary tract symptoms due to prostatic enlargement requiring surgical treatment. * Having no untreated or uncontrolled systemic disease, which refers to having an ASA (American Society of Anesthesiologists Physical Status Classification System) score III at most.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

Male

Study type

Observational

Primary location

Ondokuz Mayis University, Faculty of Medicine, Department of Urology

Samsun, Turkey (Türkiye)

Location contact

Murat Gulsen, Assistant Professor

CONTACT

[email protected]

+905062357421

About this study

Benign prostatic obstruction (BPO) is the leading cause of lower urinary tract symptoms (LUTS) among men older than 40 years.

Surgery is recommended under circumstances such as:

  • Bothersome LUTS resistant to medical treatment.
  • Acute kidney injury, bladder stone(s), resistant hematuria and urinary retention.
  • Preference of the patient.

Various surgical methods exist to treat BPO, but the most appropriate choice depends on the operator and the patient.

HoLEP is an abbreviation for holmium laser enucleation of prostate, which is one of the endoscopic laser enucleation techniques.

Both spinal and general anesthesia are applicable for HoLEP surgery. The type of anesthesia is determined by the anesthesiologist, independently of the operator's preference, taking into account several factors related to the patient, such as safety and comfort.

Controlled bleeding is one of the expected outcomes in HoLEP, and several factors determine the amount of bleeding. For HoLEP, the type of anesthesia may be one of them, as other studies have claimed. This multicenter, prospective observational study may further reveal the impact of anesthesia type on bleeding.

The amount of bleeding could be "less or more", determined according to the content below:

  • Amount of hemoglobin and hematocrit decreased, measured by laboratory examinations, preoperatively, during, and on the day after the surgery.
  • Vital changes such as hypotension, tachycardia, that require blood transfusion due to "more" bleeding during either the surgery or hospital stay after surgery.
  • Usually, a shorter duration of bladder irrigation to clean blood in the urine during hospital stay after the surgery is required for "less" bleeding.

Participants who are eligible and willing to provide informed consent will undergo HoLEP. Preoperative, perioperative, and postoperative data will be collected without disclosing the participant or any personal data relating to the participant.

Participants will be grouped into two groups based on anesthesia type: general or spinal.

To answer the main question of this study, a power analysis was conducted, concluding that at least 320 participants are required (intention-to-treat population).

All collected data will be recorded and analyzed according to the proper statistical methods. Results will be reported.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 years or older men who have BPO requiring surgical treatment.
  • Participants who can give written informed consent.
  • Having no more than 3 points for the American Society of Anesthesiologists (ASA) physical status classification scale (ASA 1 to 3).

Exclusion criteria

  • Absolute contraindication for spinal or general anesthesia
  • History of previous surgery for prostate (e.g., surgery for prostate cancer, surgery for benign prostate obstruction)
  • Uncorrected bleeding disorder (INR > 1.5)
  • Participants who are not willing to give informed consent.
  • Participants who have a proven urinary tract infection at the time of the surgery.
  • Participants who are not able to be contacted for regular follow-ups.

Treatment and study plan

Primary outcomes

  1. Hemoglobin change

    Time frame: First day after HoLEP is performed.

    Difference between preoperative and postoperative hemoglobin levels (g/dL)

Secondary outcomes

  1. International Prostate Symptom with quality of life score (IPSS-QoL) at 3 months after surgery

    Time frame: At 3 months after HoLEP

    The severity of lower urinary tract symptoms and their impact on quality of life should be assessed using a validated questionnaire.

    • 0 to 35 points for IPSS
    • 0 to 6 points for QoL Scale variable.
  2. Duration of hospitalization

    Time frame: Postoperative second to seventh days after HoLEP.

    Day(s) passed until discharge after HoLEP.

  3. Duration of catheterization

    Time frame: From the time of HoLEP until the removal of the catheter.

    Day(s) passed until the removal of the bladder drainage catheter after HoLEP.

  4. Ratio of high grade complications

    Time frame: From the time of HoLEP to 30 days after HoLEP.

    Complications will be classified according to the Clavien-Dindo classification. Clavien-Dindo Grade III or higher is considered a high-grade complication.

  5. Peak Urinary Flow (Qmax)

    Time frame: At 3 months after HoLEP.

    Peak urinary flow (mL/sec), at 3 months after HoLEP.

  6. Post-void residual (PVR)

    Time frame: At 3 months after HoLEP

    Post-void residual (PVR) volume (mL) measurement at 3 months after HoLEP

  7. Enucleation Efficiency

    Time frame: From the start of HoLEP to the end of HoLEP (Operative time).

    Weight of the enucleated adenoma per operative minute (grams/min).

  8. Ratio of intraoperative vasoactive medication requirement

    Time frame: During the anesthesia for HoLEP

    Number of participants who required vasoactive medication during anesthesia for HoLEP due to low blood pressure, as a percentage of the total number of participants.

Study contacts

Contact information is provided by the study sponsor or research team.

Murat Gulsen, Assistant Professor

CONTACT

[email protected]

+905062357421

Sponsors and collaborators

Lead sponsor

Ondokuz Mayıs University

Other

Registry information

Official study title

Does Anesthesia Type Affect HoLEP Outcomes? A Multi-Center, Real-World Comparative Study

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
May 13, 2026
Registry last updated
May 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.